| pubmed-article:8410226 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C0012984 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C0031740 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C0006118 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C1116439 | lld:lifeskim |
| pubmed-article:8410226 | lifeskim:mentions | umls-concept:C1709631 | lld:lifeskim |
| pubmed-article:8410226 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8410226 | pubmed:dateCreated | 1993-11-2 | lld:pubmed |
| pubmed-article:8410226 | pubmed:abstractText | Photodynamic therapy was studied in dogs with and without posterior fossa glioblastomas. This mode of therapy consisted of intravenous administration of Photofrin-II at doses ranging from 0.75 to 4 mg/kg 24 hours prior to laser light irradiation in the posterior fossa. Tissue levels of Photofrin-II were four times greater in the tumor than in the surrounding normal brain. Irradiation was performed using 1 hour of 500 mW laser light at a wavelength of 630 nm delivered through a fiberoptic catheter directly into the tumor bed via a burr hole. All animals receiving a high dose (4 or 2 mg/kg) of Photofrin-II developed serious brain-stem neurotoxicity resulting in death or significant residual neurological deficits. A lower dose (0.75 mg/kg) of Photofrin-II produced tumor kill without significant permanent brain-stem toxicity in either the control animals or the animals with cerebellar brain tumors receiving photodynamic therapy. | lld:pubmed |
| pubmed-article:8410226 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8410226 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8410226 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8410226 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8410226 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8410226 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8410226 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:8410226 | pubmed:issn | 0022-3085 | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:ThomasJ PJP | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:MeyerG AGA | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:MoulderJ EJE | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:SchmidtM HMH | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:MurrayK JKJ | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:WhelanH THT | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:SeguraA DAD | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:McAuliffeT... | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:StrotherD RDR | lld:pubmed |
| pubmed-article:8410226 | pubmed:author | pubmed-author:BajicD MDM | lld:pubmed |
| pubmed-article:8410226 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8410226 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:8410226 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8410226 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8410226 | pubmed:pagination | 562-8 | lld:pubmed |
| pubmed-article:8410226 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:meshHeading | pubmed-meshheading:8410226-... | lld:pubmed |
| pubmed-article:8410226 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8410226 | pubmed:articleTitle | The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. | lld:pubmed |
| pubmed-article:8410226 | pubmed:affiliation | Department of Neurology, Medical College of Wisconsin, MACC Fund Research Center, Milwaukee. | lld:pubmed |
| pubmed-article:8410226 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8410226 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8410226 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8410226 | lld:pubmed |
